Olaquindox metabolite hapten, artificial antigen and application thereof
By designing haptens that retain the quinoxaline ring and carboxyl characteristic groups of quinoline metabolites, and preparing artificial antigen and antibody combinations, the problems of expensive and insufficient sensitivity of quinoline metabolite detection equipment are solved, and a rapid and sensitive detection method is realized.
Patent Information
- Application Number
- CN202410925813.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-07-11
AI Technical Summary
Existing methods for detecting the quinolone metabolite MQCA suffer from problems such as expensive equipment, long detection time, and the need for professional personnel to operate, making rapid on-site detection impossible. Furthermore, existing hapten designs result in insufficient sensitivity of artificial antigens.
A quinoline metabolite hapten was designed, retaining the quinoxaline ring and carboxyl characteristic groups, and combining the linear structure of the active group to prepare an artificial antigen for the preparation of highly specific antibody and antigen combinations, which can be applied to immunochromatographic kits.
A rapid, sensitive, and low-cost detection method for the quinolone metabolite MQCA was achieved. The IC50 value of the ELISA detection was 0.188 μg/L, the sensitivity of the colloidal gold immunochromatography technique in the standard solution reached 1 μg/kg, and the sensitivity of the actual sample detection reached 0.5 μg/kg, with good stability.
Smart Images

Figure CN118878469A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biochemical engineering, and in particular to a quinolone metabolite hapten, an artificial antigen and applications thereof. Background Art
[0002] Olaquindox, also known as quinamide, is widely used in veterinary clinics due to its broad-spectrum antibacterial activity. However, quinolone has moderate to significant cumulative toxicity, has obvious teratogenic effects on most animals, and has potential triple toxicity to humans, i.e., teratogenicity, mutagenicity, and carcinogenicity. Therefore, quinolone is prohibited from being used as a feed additive.
[0003] Olaquindox itself is unstable and will be rapidly metabolized in animals. There are more than ten metabolites, most of which are not suitable for detection. Among them, 3-Methoxyquinoxaline-2-carboxylic acid (MQCA) is the main metabolite, which is relatively stable in the body and is a labeled residue recognized by the Codex Alimentarius Commission. Therefore, MQCA is usually used as the target for olaquindox residue analysis and monitoring. In 2003, the Ministry of Agriculture and Rural Affairs of my country stipulated that the maximum residues of MQCA in muscle and liver tissues were 4μg / kg and 50μg / kg respectively. In order to ensure the safety of animal-derived food, it is of great significance to study the method of detecting olaquindox metabolites in animal-derived food.
[0004] Among the relevant detection technologies, the detection method of quinolone metabolites is mainly based on instrumental methods. However, since the required equipment and instruments are expensive, the detection time is long, and professional personnel are required to operate, it is impossible to achieve on-site detection and rapid clinical inspection in a true sense, which brings great inconvenience to daily detection work.
[0005] The key to immunoassay detection technology is determined by the performance of antigens and antibodies, and the key to antigens and antibodies is haptens. Therefore, to obtain antigens and antibodies with excellent performance, the structural design of haptens is particularly important. In the prior art, the structural modification of MQCA haptens is based on the derivation of straight-chain active arms from the carboxyl end, and the carboxyl characteristic group directly connected to the quinoxaline ring cannot be retained, resulting in the defect of insufficient sensitivity of the prepared artificial antigen. Therefore, the development of highly specific MQCA haptens or artificial antigens is of vital importance for the rapid, highly sensitive and low-cost detection method of olaquinoxal. Summary of the invention
[0006] In order to solve the problem of lack of rapid, sensitive and simple MQCA immunoassay method for olaquindox metabolites in the prior art, the present invention provides an olaquindox metabolite hapten, an artificial antigen and applications thereof.
[0007] The first object of the present invention is to provide a hapten of olaquindox metabolite.
[0008] The second object of the present invention is to provide the use of a compound having a structural formula as shown in formula (I) in the preparation of an artificial antigen of an olaquindox metabolite.
[0009]
[0010] The third object of the present invention is to provide an artificial antigen of quinolone metabolite.
[0011] The fourth object of the present invention is to provide the use of the artificial antigen of olaquindox metabolite in the preparation of antibodies for detecting olaquindox metabolites.
[0012] The fifth object of the present invention is to provide an artificial antigen combination of olaquindox metabolites.
[0013] The sixth object of the present invention is to provide the use of the artificial antigen combination of olaquindox metabolites in the preparation of products for detecting olaquindox metabolites.
[0014] The seventh object of the present invention is to provide a kit for detecting olaquinoxaline metabolites.
[0015] In order to achieve the above object, the present invention is implemented by the following scheme:
[0016] The hapten prepared by the present invention completely retains the characteristic group of the quinoxaline ring in the quinoxaline metabolite, and also retains the carboxyl group connected to the quinoxaline ring, and the designed coupling arm is a straight chain with an active group, so that the small molecule structure on the prepared artificial antigen retains the original characteristics intact, is more conducive to presenting the structural characteristics of the quinoxaline metabolite, and improves the immunogenicity of the antigen.
[0017] A hapten of quinolone metabolite, the structural formula of which is shown in formula (I),
[0018]
[0019] The preparation method of the compound with the structural formula shown in formula (I) comprises the following steps: compound a reacts under acidic conditions to obtain compound b; compound b and compound c react fully to obtain;
[0020]
[0021] The compound a is 3-methylquinoxaline-2-carboxylic acid, and its structural formula is The structural formula of the compound b is The structural formula of the compound c is
[0022] Preferably, the compound a is reacted under acidic conditions to obtain the compound b, comprising the following steps: fully reacting the compound a with hydrobromic acid, adjusting the pH of the obtained reactant to 4-5, then extracting with n-butanol, collecting the obtained organic phase, performing solid-liquid separation, collecting the precipitate, and obtaining a crude compound b.
[0023] Preferably, the compound b and compound c are fully reacted, comprising the following steps: fully reacting the compound b, potassium carbonate and the compound c, extracting the obtained reactant with ethyl acetate, collecting the obtained aqueous phase, adjusting the pH to 4-5, collecting the precipitated solid, and then washing it with a methanol-ethyl acetate solution to obtain.
[0024] More preferably, the molar ratio of the compound b to the compound c is 1:(1.5-3).
[0025] Further preferably, the molar ratio of the compound b to the compound c is 1:2.
[0026] More preferably, in the methanol-ethyl acetate solution, the volume ratio of methanol to ethyl acetate is 1:(2-6).
[0027] Further preferably, in the methanol-ethyl acetate solution, the volume ratio of methanol to ethyl acetate is 1:4.
[0028] Specifically, the method for preparing the compound having the structural formula (I) comprises the following steps:
[0029] 200 mg of compound a (MQCA, CAS No.: 55495-69-7, 0.98 mmol) was placed in a 50 ml round-bottom flask, and 5 ml of hydrobromic acid aqueous solution (content 48%) was added. The resulting reaction mixture was reacted at 60°C for 3-5 hours. After the reaction was completed, 40 ml of purified water was added, and the pH value was adjusted to 4-5 with solid sodium bicarbonate. N-butanol was added for extraction twice, and the organic phases were combined and evaporated to dryness under reduced pressure to obtain 184 mg of crude compound b;
[0030] Dissolve 184 mg of crude compound b (0.97 mmol) in 5 ml of dimethylformamide (DMF), then add 268 mg of potassium carbonate (1.94 mmol) and 237 mg of compound c (1.94 mmol) in sequence, stir well, and react the reaction mixture at RT for 8 to 12 hours. After the reaction is complete, add 30 ml of pure water, extract twice with ethyl acetate, adjust the pH value of the aqueous phase to 4 to 5 with 4M hydrochloric acid, and collect the precipitated solid. Wash the obtained solid three times with a 20% methanol / ethyl acetate (V:V) mixture, and dry it to obtain the product.
[0031] The use of the compound represented by the structural formula (I) in the preparation of artificial antigens of olaquindox metabolites should also be within the scope of protection of the present invention.
[0032]
[0033] An artificial antigen of quinolone metabolite, whose structural formula is shown in formula (II),
[0034]
[0035] Among them, Protein is a carrier protein.
[0036] Preferably, the carrier protein is bovine serum albumin or lactoferrin.
[0037] The method for preparing the artificial antigen of olaquindox metabolite comprises the following steps: coupling the olaquindox metabolite hapten with a carrier protein under acidic conditions to obtain the artificial antigen.
[0038] Preferably, the method comprises the following steps: fully reacting the quinolone metabolite hapten with the activator and the carrier protein, fully reacting the obtained reactant with sodium borohydride, and dialyzing to obtain the product.
[0039] More preferably, the solvent for the reaction is dimethylformamide.
[0040] Specifically, the carrier protein is bovine serum albumin, and the method for preparing the artificial antigen of quinolone metabolite comprises the following steps:
[0041] Take 50 mg of bovine serum albumin and fully dissolve it in 5 mL of MES buffer at pH 6.0 to obtain a carrier protein solution; take 10 mg of the quinolone metabolite hapten and fully dissolve it in 0.5 mL of DMF, and add it dropwise to the carrier protein solution under stirring, and stir it at room temperature in the dark for 16 to 24 hours to obtain a carrier protein activation solution; take 50 mg of sodium borohydride and dissolve it in 0.5 mL of ice water, and add it dropwise to the carrier protein activation solution under stirring, and stir it at room temperature in the dark for 1 to 2 hours, then dialyze the obtained solution with 0.01 mol / L PBS at room temperature for 3 days, and change the dialysate 3 times a day. The obtained dialyzate product is the quinolone metabolite artificial antigen.
[0042] Specifically, the carrier protein is lactoferrin, and the method for preparing the artificial antigen of quinolone metabolite comprises the following steps:
[0043] Take 30 mg of lactoferrin and fully dissolve it in 3 mL of MES buffer at pH 6.0 to obtain a carrier protein solution; take 4 mg of the quinolone metabolite hapten and fully dissolve it in 0.2 mL of DMF, and add it dropwise to the carrier protein solution under stirring, and stir it at room temperature in the dark for 16 to 24 hours to obtain a carrier protein activation solution; take 30 mg of sodium borohydride and dissolve it in 0.8 mL of ice water, and add it dropwise to the carrier protein activation solution under stirring, and stir it at room temperature in the dark for 1 to 2 hours; then dialyze the obtained solution with 0.01 mol / L PBS at room temperature for 3 days, changing the dialysate 3 times a day, and the obtained dialyzate product is the quinolone metabolite artificial antigen.
[0044] The use of any of the artificial antigens of olaquindox metabolites in the preparation of antibodies for detecting olaquindox metabolites should also be within the protection scope of the present invention.
[0045] The invention discloses an antibody to quinolone metabolite, which is prepared by immunizing an animal with the artificial antigen of quinolone metabolite whose carrier protein is hemocyanin as an immunogen.
[0046] Preferably, the quinolone metabolite antibody is a monoclonal antibody, which is obtained by immunizing animals with the above-mentioned quinolone metabolite artificial antigen whose carrier protein is hemocyanin as an immunogen to obtain hybridoma cells, culturing the obtained hybridoma cells and collecting the cells for animal immunization to obtain ascites, and then identifying and purifying the monoclonal antibody.
[0047] An artificial antigen combination of olaquindox metabolites comprises a coating agent and an immunogen, wherein the coating agent is obtained by coupling the olaquindox metabolite hapten with bovine serum albumin; and the immunogen is obtained by coupling the olaquindox metabolite hapten with lactoferrin.
[0048] The use of the olaquindox metabolite artificial antigen combination in the preparation of products for detecting olaquindox metabolites should also be within the protection scope of the present invention.
[0049] Preferably, the olaquinoxaline metabolite is 3-methylquinoxaline-2-carboxylic acid.
[0050] A kit for detecting quinolone metabolites comprises the quinolone metabolite artificial antigen combination.
[0051] Preferably, it comprises an immunochromatographic test strip and a microwell; the immunochromatographic test strip comprises a bottom plate, on which a sample pad, a coated reaction membrane and a water-absorbing pad which are overlapped in sequence are arranged, the reaction membrane is a nitrocellulose membrane provided with a detection area and a quality control area, the detection area is coated with the coating antigen in the artificial antigen combination of quinolone metabolites, and the quality control area is coated with IgG; the microwell is equipped with an antibody for detecting quinolone metabolites, and the antibody is prepared from the immunogen in the artificial antigen combination of quinolone metabolites.
[0052] Preferably, the sample pad is soaked in a sample treatment solution, which is a 0.1 M PB buffer solution containing 0.3% wt Tween 20, 1% wt sucrose, 0.5% wt BSA and 0.05% wt sodium azide.
[0053] Preferably, the IgG is murine IgG.
[0054] Specifically, the preparation method of the coated reaction membrane includes the following steps: using nitrocellulose membrane as the reaction membrane, adjusting the concentration of the coating source to 0.05-0.2 mg / mL with a coating buffer to obtain a detection coating source solution; and adjusting the concentration of mouse IgG to 0.1-0.5 mg / mL with a coating buffer to obtain a quality control coating source solution; according to a membrane liquid volume of 0.8-1.2 μL / cm, spraying the detection coating source solution and the quality control coating source solution onto the detection area and control area corresponding to the reaction membrane, respectively, with an interval of 2.5 mm between the detection area and the control area, and placing in a 45°C oven for 12-16 hours to obtain; the coating buffer is a 0.1M PB buffer containing 1wt% sucrose and 0.05wt% sodium azide, with a pH of 7.4.
[0055] Preferably, the quinolone metabolite antibody is a monoclonal antibody, which is obtained by immunizing animals with the above-mentioned quinolone metabolite artificial antigen whose carrier protein is hemocyanin as an immunogen to obtain hybridoma cells, culturing the obtained hybridoma cells and collecting the cells for animal immunization to obtain ascites, and then identifying and purifying the monoclonal antibody.
[0056] More preferably, the monoclonal antibody is labeled with colloidal gold.
[0057] Further preferably, the method for labeling the monoclonal antibody with colloidal gold comprises the following steps: taking 1g of chloroauric acid, dissolving it with pure water and ultrasound, and then fixing the volume to 100ml to obtain a chloroauric acid solution; taking 1ml of the chloroauric acid solution to 100ml of pure water, heating it to boiling, adding 0.5ml of 0.06wt% sodium citrate solution, continuing to heat for 10 minutes, cooling it to room temperature, and adding pure water to a volume of 100ml to obtain a nanogold solution;
[0058] The pH value of the colloidal gold solution was adjusted with 0.1 mol / L K2CO3 and 0.1 mol / L HCl respectively (the amount added was the minimum amount used when the subsequent labeling process did not change color); 5 μg of the monoclonal antibody was added to the nanogold solution with different pH values, reacted at room temperature for 5 minutes, and the color change of the solution was observed, and the pH value that kept the solution red was recorded. 10 μl of 10 wt% BSA was added for blocking, centrifuged at 12,000 rpm, all the clear liquid was discarded, and the resulting precipitate was collected to obtain the product.
[0059] Compared with the prior art, the present invention has the following beneficial effects:
[0060] The artificial antigen and monoclonal antibody prepared from the quinolone metabolite hapten provided by the present invention are used for ELISA detection with strong specificity, IC 50 The value is 0.188 μg / L. The present invention also establishes a colloidal gold immunochromatography technology for detecting the quinolone metabolite MQCA, which quickly and conveniently realizes the qualitative detection of MQCA, with a sensitivity of 1 μg / kg in the standard solution and a detection sensitivity of 0.5 μg / kg in the actual sample, and has good stability, meeting the requirements of storage, transportation and use in market applications. BRIEF DESCRIPTION OF THE DRAWINGS
[0061] Figure 1 This is a synthetic route for the hapten of quinolone metabolite.
[0062] Figure 2 The mass spectrometry results of quinolone metabolite hapten.
[0063] Figure 3 This is the synthetic route of artificial antigen of quinolone metabolite.
[0064] Figure 4 is the standard curve of MQCA standard solution. DETAILED DESCRIPTION
[0065] The present invention is further described in detail below in conjunction with the accompanying drawings and specific examples of the specification. The examples are only used to explain the present invention and are not used to limit the scope of the present invention. The test methods used in the following examples are conventional methods unless otherwise specified; the materials and reagents used are reagents and materials that can be obtained from commercial channels unless otherwise specified.
[0066] Example 1 Preparation and Identification of Olaquindox Metabolite Haptens
[0067] 1. Preparation of quinolone metabolite hapten
[0068] According to Figure 1 The synthetic route shown is used to prepare the quinolone metabolite hapten, and the specific steps are as follows:
[0069] (1) 200 mg of compound a (MQCA, CAS No.: 55495-69-7, 0.98 mmol) was placed in a 50 ml round-bottom flask, and 5 ml of hydrobromic acid aqueous solution (48% by mass) was added. The resulting reaction mixture was reacted at 60° C. for 3 to 5 h. After the reaction was completed, 40 ml of purified water was added, and the pH value was adjusted to 4 to 5 with solid sodium bicarbonate. N-butanol was added for extraction twice, and the organic phases were combined and evaporated to dryness under reduced pressure to obtain 184 mg of crude compound b.
[0070] (2) Dissolve 184 mg of crude compound b (0.97 mmol) in 5 ml of dimethylformamide (DMF), then add 268 mg of potassium carbonate (1.94 mmol) and 237 mg of compound c (1.94 mmol) in turn. After stirring thoroughly, the reaction mixture is reacted at RT for 8 to 12 hours. After the reaction is completed, add 30 ml of pure water and extract twice with ethyl acetate. The pH value of the aqueous phase is adjusted to 4 to 5 with 4 M hydrochloric acid, and the precipitated solid is collected. The solid is washed three times with a 20% methanol-ethyl acetate mixture (i.e., the volume ratio of methanol to ethyl acetate is 20:80), and dried to obtain 85 mg of quinolone metabolite hapten.
[0071] 2. Identification of quinolone metabolite haptens
[0072] The structural formula of the hapten of quinolone metabolite is shown in formula (I):
[0073]
[0074] The mass spectrometry results of quinolone metabolite hapten are as follows Figure 2 As shown, specifically: 231(M-1).
[0075] Example 2 Preparation and Identification of Artificial Antigens of Oquindox Metabolites
[0076] The structural formula of the olaquindox metabolite artificial antigen provided by the present invention is shown in formula (II),
[0077]
[0078] Protein is a carrier protein, and the carrier protein is bovine serum albumin (BSA) or lactoferrin (LF).
[0079] According to Figure 3 The synthetic route shown is used to prepare the artificial antigen of quinolone metabolite.
[0080] 1. The specific steps for preparing artificial antigens of quinolone metabolites with BSA as carrier protein are as follows:
[0081] (1) Weigh 50 mg of BSA and fully dissolve it in 5 mL of MES buffer (pH 6.0) to obtain a carrier protein solution;
[0082] (2) 10 mg of the quinolone metabolite hapten prepared in Example 1 was fully dissolved in 0.5 mL of DMF, and added dropwise to the carrier protein solution prepared in step (1) under stirring, and stirred at room temperature in the dark for 16 to 24 h to obtain a carrier protein activation solution;
[0083] (3) Dissolve 50 mg of sodium borohydride in 0.5 mL of ice water, add dropwise to the carrier protein activation solution prepared in step (2) under stirring, and stir at room temperature in the dark for 1 to 2 h;
[0084] (4) dialyzing the solution obtained in step (3) with 0.01 mol / L PBS at room temperature for 3 days, changing the dialysate 3 times a day to remove unreacted small molecules, and the resulting dialyzate is the artificial antigen of quinolone metabolite;
[0085] (5) Aliquot and store at 4°C until needed.
[0086] 2. The specific steps for preparing artificial antigens of quinolone metabolites with LF as carrier protein are as follows:
[0087] (1) Weigh 30 mg of LF and fully dissolve it in 3 mL of MES buffer (pH 6.0) to obtain a carrier protein solution;
[0088] (2) 4 mg of the quinolone metabolite hapten prepared in Example 1 was fully dissolved in 0.2 mL of DMF, and added dropwise to the carrier protein solution prepared in step (1) under stirring, and stirred at room temperature in the dark for 16 to 24 h to obtain a carrier protein activation solution;
[0089] (3) Dissolve 30 mg of sodium borohydride in 0.8 mL of ice water, add dropwise to the carrier protein activation solution prepared in step (2) under stirring, and stir at room temperature in the dark for 1 to 2 h;
[0090] (4) dialyzing the solution obtained in step (3) with 0.01 mol / L PBS at room temperature for 3 days, changing the dialysate 3 times a day to remove unreacted small molecules, and the resulting dialyzate is the artificial antigen of quinolone metabolite;
[0091] (5) Aliquot and store at 4°C until needed.
[0092] Example 3 Preparation of monoclonal antibodies to quinolone metabolites
[0093] 1. Animal immunization
[0094] The artificial antigen of quinolone metabolite with LF as carrier protein prepared in Example 2 was used as an immunogen, and after being emulsified with an equal volume of Freund's adjuvant, BALB / C mice were immunized, and the immunization dose for each mouse was 50 μg to 100 μg. The immunization interval was 2 weeks, and after 3 immunizations, the serum titer was tested by collecting venous blood from the tail of the mice. If the antibody titer does not meet the requirements, booster immunization is required.
[0095] After the antibody titer stopped increasing, subcutaneous booster immunization was performed with 100 μg of whole antigen.
[0096] 2. Hybridoma cell preparation
[0097] Five days after the last booster immunization, mouse spleen cells were taken and fused with human osteosarcoma SP20 cells. The fused cells were selected in HAT medium and cultured in HAT medium after five days with complete medium replaced with HAT medium.
[0098] The cell supernatant was tested by ELISA, and the cells in the wells with strongly positive test results were cloned and cultured by limiting dilution method. After three clone culture tests, the cells in the wells that were positive were hybridoma cells that secreted monoclonal antibodies.
[0099] 3. Monoclonal Antibody Preparation
[0100] After the hybridoma cells are amplified and cultured, they are inoculated into the peritoneal cavity of mice to produce ascites containing antibodies. The ascites is purified by the caprylic acid-ammonium sulfate precipitation method to obtain a highly pure and highly specific monoclonal antibody against the quinolone metabolite.
[0101] Example 4 ELISA performance evaluation
[0102] 1. Experimental methods
[0103] The performance of the artificial antigen and monoclonal antibody prepared by the present invention is evaluated by ELISA method, which comprises the following steps:
[0104] (1) Antigen coating
[0105] The quinolone metabolite artificial antigen prepared in Example 2 with BSA as carrier protein was diluted to 0.08 μg / mL using carbonate buffer at pH 9.6 as coating diluent, and added to a polystyrene microplate at 100 μL / well, coated overnight at 4°C, dried, and washed three times with PBST.
[0106] (2) Closed
[0107] 280 μL / well of phosphate buffer containing 1% wt BSA was added, the cells were blocked at 37°C for 1 h, dried, washed three times with PBST, dried, and vacuum packed for storage.
[0108] (3) Primary antibody dilution
[0109] The monoclonal antibody against quinolone metabolites prepared in Example 3 was diluted to 0.1 μg / mL using a phosphate buffer (pH 7.4) containing 0.05% wt sodium azide and stored at 4°C for later use.
[0110] (4) Preparation of standard solution
[0111] The MQCA standard was dissolved in 0.01 M PBS to obtain MQCA standard solutions with concentrations of 0 μg / L, 0.5 μg / L, 1.5 μg / L, 4.5 μg / L, 13.5 μg / L and 40.5 μg / L, respectively.
[0112] (5) Sample addition and primary antibody incubation
[0113] 100 μL / well of MQCA standard solution of each concentration was added to the microwells of the ELISA plate coated with artificial antigen of quinolone metabolite, and then 20 μL / well of quinolone metabolite monoclonal antibody solution was added accordingly, reacted at 37°C for 0.5h, and then dried.
[0114] (6) Washing the primary antibody
[0115] Add 280 μL / well PBST, wash 3 times and pat dry.
[0116] (7) Secondary antibody incubation
[0117] Add 100 μL / well of HRP enzyme-labeled goat anti-mouse IgG secondary antibody and react at 37°C for 0.5 h.
[0118] (8) Washing the secondary antibody
[0119] Add 280 μL / well PBST, wash again 3 times and pat dry.
[0120] (9) Color rendering
[0121] Add 100 μL / well TMB colorimetric solution and react at 37°C for 15 min; add 50 μL / well 1 M sulfuric acid to stop color development.
[0122] (10) Absorbance determination
[0123] Place the microwell ELISA plate obtained in the previous step into an ELISA reader, and set the ELISA reader to measure the OD value of each well at a wavelength of 450 nm.
[0124] 2. Experimental results
[0125] Table 1 OD values of MQCA standard solutions of different concentrations determined by ELISA
[0126]
[0127] The OD value measurement results of MQCA standard solutions with different concentrations are shown in Table 1. Based on the data shown in Table 1, ELISA Calc software was used to perform four-parameter Logistic curve fitting, and the following was obtained: Figure 4 The linear equation of the standard curve shown is: y = (AD) / [1 + (x / C) ^ B] + D, r 2=0.99928; where A = 1.12999, B = 0.89404, C = 0.13580, D = 0.14166, x represents the concentration of the substance to be tested, and y represents the OD value. IC 50 The value is 0.188μg / L, and it is linear in the range of 0.04μg / L to 3.24μg / L.
[0128] Example 5 A colloidal gold qualitative immunochromatographic kit for detecting quinolone metabolites
[0129] 1. Composition of the kit
[0130] (1) Colloidal gold qualitative immunochromatographic test paper card
[0131] The colloidal gold qualitative immunochromatographic test paper card contained in this kit is prepared by the following method:
[0132] Preparation of coated reaction membrane: Using nitrocellulose membrane (NC membrane) as the reaction membrane, the concentration of the artificial antigen of quinolone metabolite of BSA with carrier protein prepared in Example 2 was adjusted to 0.05-0.2 mg / mL with coating buffer (0.1M PB buffer containing 1wt% sucrose and 0.05wt% sodium azide, pH = 7.4) to obtain a detection coating original solution; and the concentration of mouse IgG was also adjusted to 0.1-0.5 mg / mL with coating buffer to obtain a quality control coating original solution; according to the membrane liquid volume of 0.8-1.2 μL / cm, the detection coating original solution and the quality control coating original solution were sprayed onto the detection area (T line) and control area (C line) corresponding to the reaction membrane, respectively, with an interval of 2.5 mm between the detection area and the control area, and placed in a 45°C oven for 12-16 h to obtain a coated reaction membrane, which was placed in a constant temperature and humidity storage box for standby.
[0133] Preparation of sample pad: Soak the cut 30×30cm blank sample pad in the sample treatment solution (0.01M PBT buffer containing 0.05wt% Tween 20, 1wt% sucrose, 0.1wt% BSA and 0.05wt% sodium azide) for 5 minutes, then take out and dry at 37℃ for 16 hours to obtain the sample pad, and place it in a constant temperature and humidity storage box for use.
[0134] Assembly: Paste the sample pad, coated reaction membrane and absorbent pad in the middle of the PVC board, overlap the sample pad, coated reaction membrane and absorbent pad in sequence, where the absorbent pad is adjacent to the control area of the coated reaction membrane, and the sample pad is adjacent to the detection area of the coated reaction membrane, and the test paper is obtained. Cut the test paper into test strips with a width of 3mm, and then load them into the test paper card, with the sample pad adjacent to the sample addition hole, to obtain the colloidal gold qualitative immunochromatography test paper card.
[0135] (2) Gold-labeled micropores
[0136] The gold-labeled microwells included in this kit were prepared by the following method:
[0137] Preparation of nano gold solution: Take 1g of chloroauric acid, dissolve it with pure water and ultrasound, and then dilute it to 100ml to obtain chloroauric acid solution, which is stored at 4°C away from light for later use. Take 1ml of chloroauric acid solution to 100ml of pure water, heat it to boiling, then add 0.5ml of 0.06wt% sodium citrate solution, continue heating for 10 minutes, cool it to room temperature, add pure water to a volume of 100ml, and obtain a nano gold solution, which is stored at room temperature away from light for later use. All glassware used needs to be soaked in a mixture of potassium permanganate and sulfuric acid overnight, and then washed and dried before use.
[0138] Labeling of monoclonal antibody to quinolone metabolites: The nanogold solution was divided into 1 ml / bottle, and the pH value of the colloidal gold solution was adjusted with 0.1 mol / L K2CO3 and 0.1 mol / L HCl respectively (the amount added was the minimum amount used when the subsequent labeling process did not change color); 5 μg of the monoclonal antibody to quinolone metabolites prepared in Example 3 was added to the nanogold solutions of different pH values, reacted at room temperature for 5 minutes, and the color change of the solution was observed, and the pH value that kept the solution red was recorded. 10 μl of 10 wt% BSA was added for blocking, centrifuged at 12,000 rpm, and all the clear liquid was discarded. The resulting precipitate was the monoclonal antibody to quinolone metabolites labeled with nanogold.
[0139] Packaging of gold-labeled microwells: Use 1 ml of gold diluent (water containing 2wt% Tris, 5wt% BSA, 0.05wt% thimerosal and 5wt% sucrose) to reconstitute the gold-labeled quinalkonium metabolite monoclonal antibody, dispense it into the microwells at 20μl / well, dry it at 37°C for 16 hours, and you will get the gold-labeled microwells, which are stored for later use.
[0140] 2. How to use the kit
[0141] (1) Detection
[0142] The solution to be tested was added to the gold-labeled microwells at 100 μl / well, and the solution was repeatedly blown to make it evenly redissolved; after standing for 3 minutes, the solution in the gold-labeled microwells was transferred to the sample wells of the colloidal gold qualitative immunochromatographic test paper card, and the timing was started after the sample was added. The results can be observed after 5 to 8 minutes, and the result is invalid after 8 minutes. The test was repeated for 3 groups.
[0143] (2) Visual interpretation
[0144] Observe the color of the T line and C line of the colloidal gold qualitative immunochromatographic test paper card. When the color of the T line is stronger than that of the C line or there is no obvious difference with the color of the C line, it means the test result is negative (-); when the color of the T line is significantly weaker than that of the C line or the T line does not show color, it means the test result is positive (+); when the C line does not show color, it indicates that the test result is invalid due to incorrect operation process or the test strip has expired.
[0145] Example 6 Performance Evaluation of Colloidal Gold Qualitative Immunochromatography Kit
[0146] 1. Sensitivity
[0147] The MQCA standard was diluted with 0.01 M PBS buffer to obtain MQCA standard solutions of different concentrations, which were used as test solutions and detected using the colloidal gold qualitative immunochromatography kit of Example 5. The experiment was repeated for 3 groups.
[0148] The results are shown in Table 2, which shows that the detection limit of the kit for quinolone metabolite MQCA is as low as 1 μg / L, with high sensitivity.
[0149] Table 2 Determination results of different concentrations of quinolone metabolite standard solutions
[0150]
[0151] Note: “+” represents positive, “-” represents negative.
[0152] 2. Stability
[0153] The colloidal gold qualitative immunochromatographic test paper card is stored at room temperature. In order to evaluate its stability, an accelerated destructive test is performed and the card is placed at 45°C for 60 consecutive days.
[0154] On day 0, day 5, day 10, day 20, day 30, day 40, day 50 and day 60, the MQCA standard was diluted with 0.01 M PBS buffer to obtain MQCA standard solutions of different concentrations, which were used as test solutions and detected using the colloidal gold qualitative immunochromatography kit of Example 5. The experiment was repeated in 3 groups.
[0155] As shown in Table 3, it can be seen that after being sealed and stored at room temperature and 45°C for 60 days, the T / C color depth interpretation results of the colloidal gold qualitative immunochromatographic test strips have no obvious changes, indicating that the colloidal gold qualitative immunochromatographic test strips can be stably stored for at least 60 days at 45°C in the accelerated experiment. Therefore, the olaquindox metabolite colloidal gold qualitative immunochromatographic test strips prepared by the present invention can be stably stored at room temperature for more than one year, meeting the market requirements during storage and transportation.
[0156] Table 3 Accelerated destructive test results
[0157]
[0158] 3. Spiked testing of actual tissue samples
[0159] Take 2g of fat-free and homogenized tissue sample (muscle tissue) in a 15mL centrifuge tube, add 3mL of acetonitrile and 2g of sodium sulfate solid, and shake or shake thoroughly for 1min; after mixing, centrifuge at 4000r / min at room temperature for 5min, take 2.5mL of supernatant and blow dry under 75℃ nitrogen or air; add 0.5mL of n-hexane and 0.3mL of 0.01M PBS buffer to the residue, mix thoroughly and let stand to separate (if emulsification occurs, put it in an 80℃ water bath for 5min, or centrifuge at 4000r / min at room temperature for 2min); discard the upper layer of liquid and collect the lower layer as the test solution; use the colloidal gold qualitative immunochromatography kit of Example 5 for detection, and set up 3 groups of replicates in the experiment.
[0160] Minimum detection limit: 10 blank samples were subjected to gradient spike detection using quinolone metabolite standard solution with the spike increments of 0μg / kg, 0.15μg / kg, 0.5μg / kg, 1μg / kg and 2μg / kg.
[0161] As shown in Table 4, the test results of the 10 samples were reproducible. When the content of quinolone metabolites in the samples was lower than 0.5 μg / kg, they were all negative; when it was higher than 0.5 μg / kg, they were all positive. This kit can detect MQCA in actual tissue samples, with a detection limit as low as 0.5 μg / kg.
[0162] Table 4. Results of spiked test of actual tissue samples
[0163]
[0164] Note: 1 and 2 are from different markets.
[0165] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit the protection scope of the present invention. For ordinary technicians in this field, other different forms of changes or modifications can be made based on the above descriptions and ideas. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.
Claims
1. A hapten of quinolone metabolite, characterized in that: Its structural formula is shown in formula (I).
2. Use of a compound having a structural formula (I) in the preparation of an artificial antigen of olaquindox metabolite, 3. An artificial antigen of quinolone metabolite, characterized in that: Its structural formula is shown in formula (II). Among them, Protein is a carrier protein.
4. The artificial antigen of quinolone metabolite according to claim 3, characterized in that The carrier protein is bovine serum albumin or lactoferrin.
5. Use of the artificial antigen of olaquindox metabolite according to claim 3 or 4 in the preparation of antibodies for detecting olaquindox metabolites.
6. An artificial antigen combination of quinolone metabolites, characterized in that: The invention comprises a coating agent and an immunogen, wherein the coating agent is obtained by coupling the hapten of the olaquindox metabolite according to claim 1 with bovine serum albumin; and the immunogen is obtained by coupling the hapten of the olaquindox metabolite according to claim 1 with lactoferrin.
7. Use of the artificial antigen combination of olaquindox metabolites according to claim 6 in the preparation of products for detecting olaquindox metabolites.
8. The use according to claim 7, characterized in that: The olaquinoxaline metabolite is 3-methylquinoxaline-2-carboxylic acid.
9. A kit for detecting quinolone metabolites, characterized in that: The invention comprises the artificial antigen combination of quinolone metabolites as described in claim 6.
10. The kit according to claim 9, characterized in that Contains immunochromatographic test strips and microwells; The immunochromatographic test strip comprises a bottom plate, on which a sample pad, a coated reaction membrane and a water-absorbing pad are arranged in sequence, the reaction membrane is a nitrocellulose membrane with a detection area and a quality control area, the detection area is coated with the coating source described in claim 6, and the quality control area is coated with IgG; The microwells are loaded with antibodies for detecting quinolone metabolites, and the antibodies are prepared from the immunogen described in claim 6.
Citation Information
Patent Citations
Preparation method and applications of olaquindox metabolite hapten
CN103304495A
Semiantigen, artificial antigen thereof, and application of semiantigen in detection of olaquindox residual marker
CN105061339A
Olaquindox metabolin antigen, antibody, enzyme-linked immunosorbent assay kit and detection method
CN109180519A
Method and product for detecting olaquindox content in veterinary drug preparation
CN109734675A
